Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not

Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not

While PARP inhibitors such as rucaparib and olaparib have shown activity in metastatic castration-resistant prostate cancer, they have failed to show a clear improvement in hard outcomes such as overall survival or quality of life. Because of methodological limitations, we suggest caution before imp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European urology 2024-01, Vol.85 (1), p.1-2
Hauptverfasser: González-Padilla, Daniel A., Subiela, José Daniel
Format: Artikel
Sprache:eng
Schlagworte:
BRCA1 Protein
BRCA2 Protein
Humans
Male
Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Prostatic Neoplasms, Castration-Resistant - pathology
Quality of Life
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:While PARP inhibitors such as rucaparib and olaparib have shown activity in metastatic castration-resistant prostate cancer, they have failed to show a clear improvement in hard outcomes such as overall survival or quality of life. Because of methodological limitations, we suggest caution before implementing these treatments in routine clinical practice; offering them to patients without a BRCA1/2 mutation is probably inappropriate.
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2023.05.017